The Sarasota Architectural Foundation (SAF) today announced that pharmaceutical executive David Zaccardelli has joined its Board of Directors.
“Dave brings both depth and breadth of expertise from his fruitful career accomplishments to our nonprofit organization,” said Anne Marie Bergevin, co-chair of the SAF board. “Since moving to Sarasota, he has fully embraced our community’s passion for the Sarasota School of Architecture movement by acquiring one of its prominent buildings as his own personal residence in the spirit of preserving those mid-century treasures. We are thrilled to have him join our board.
Zaccardelli, who earned a doctorate in pharmacy (Pharm.D.) from the University of Michigan, has enjoyed a successful career in the pharmaceutical industry and as an entrepreneur. He served in several senior management roles, including acting CEO of Cempra Pharmaceuticals and chief operating officer, chief manufacturing officer and executive vice president of United Therapeutics Corporation. Zaccardelli also founded and led a startup company focused on contract pharmaceutical development services.
Zaccardelli currently serves on the board of directors of Melinta Therapeutics, Evecxia, Inc. and CoreRx, Inc.
SAF’s mission is to educate, advocate and celebrate the legacy of the Sarasota School of Architecture. Its Board of Directors is comprised of individuals from the design, medical, business, academic and volunteer communities of Sarasota.
For more information, visit sarasotaarchitecturalfoundation.org.